• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Allergan to buy Pa.-based Vicept

Article

Allergan will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.

Irvine, Calif. - Allergan, based here, will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.

Allergan will pay $75 million for the company, based in Malvern, Pa., and up to $200 million in future milestone payments. Vicept’s V-101, a cream for treating redness associated with rosacea, is in mid-stage clinical trials. Vicept has two other products in the early stages of development.

An Allergan spokesman said the acquisition enhances the company’s dermatology research and development pipeline.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.